G&E Herbal Biotechnology Co., Ltd., a biotechnology company, focuses on the development and commercialization of novel botanical extraction technology and products in Taiwan.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$24.65|
|52 Week High||NT$22.90|
|52 Week Low||NT$40.00|
|1 Month Change||2.71%|
|3 Month Change||-13.66%|
|1 Year Change||-36.63%|
|3 Year Change||-36.31%|
|5 Year Change||-74.08%|
|Change since IPO||-53.80%|
Recent News & Updates
G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|4911||TW Personal Products||TW Market|
Return vs Industry: 4911 underperformed the TW Personal Products industry which returned -15.1% over the past year.
Return vs Market: 4911 underperformed the TW Market which returned 36.1% over the past year.
Stable Share Price: 4911 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4911's weekly volatility (3%) has been stable over the past year.
About the Company
G&E Herbal Biotechnology Co., Ltd., a biotechnology company, focuses on the development and commercialization of novel botanical extraction technology and products in Taiwan. It offers hepato protective agent capsules for the treatment of chronic liver inflammation, cirrhosis, hepatitis, and other liver diseases; botanical anti-aging cosmetic products; and SR-100 skin repair gel. The company also provides botanical healthcare products, such as Astragali Radix for physical strength; Goji for eyes; and Prosta capsule for regulating physiological functions and boosting metabolism, as well as offers adult products.
G&E Herbal Biotechnology Fundamentals Summary
|4911 fundamental statistics|
Is 4911 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4911 income statement (TTM)|
|Cost of Revenue||NT$17.10m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.24|
|Net Profit Margin||-42.76%|
How did 4911 perform over the long term?See historical performance and comparison
Is G&E Herbal Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4911's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4911's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4911 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.
PE vs Market: 4911 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4911's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4911's PB Ratio (2x) is in line with the TW Personal Products industry average.
How is G&E Herbal Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as G&E Herbal Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has G&E Herbal Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4911 is currently unprofitable.
Growing Profit Margin: 4911 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4911 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare 4911's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4911 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).
Return on Equity
High ROE: 4911 has a negative Return on Equity (-1.9%), as it is currently unprofitable.
How is G&E Herbal Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 4911's short term assets (NT$141.6M) exceed its short term liabilities (NT$8.6M).
Long Term Liabilities: 4911 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 4911 is debt free.
Reducing Debt: 4911 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4911 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4911 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 42.8% each year
What is G&E Herbal Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4911's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4911's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4911's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4911's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 4911 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4911's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
G&E Herbal Biotechnology has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
G&E Herbal Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources
- Name: G&E Herbal Biotechnology Co., Ltd.
- Ticker: 4911
- Exchange: TPEX
- Founded: 2002
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$1.372b
- Shares outstanding: 55.66m
- Website: https://www.geherbs.com.tw
Number of Employees
- G&E Herbal Biotechnology Co., Ltd.
- No.92, Keji 5th Road
- Annan District
- Tainan City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 15:20|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.